Diaphragm Function After Reversal of Rocuronium-induced Neuromuscular Blockade With Sugammadex or Neostigmine in Children
Neuromuscular Block, Residual
About this trial
This is an interventional prevention trial for Neuromuscular Block, Residual
Eligibility Criteria
Inclusion Criteria: Patients between the ages of 2 and 7 who are scheduled for surgery lasting more than 1 hour under general anesthesia using a neuromuscular blocking agent Exclusion Criteria: Patients with a history of severe respiratory disease with a high risk of bronchoconstriction Patients with abnormal findings on preoperative chest radiography such as severe atelectasis, pneumothorax, pleural effusion, or pneumonia. Patients with severe renal or liver disease, or neuromuscular disease Patients with a history of allergy to drugs (sugammadex, rocuronium neostigmine) Patients with significant bradycardia Patients scheduled for surgery where estimated blood loss during surgery is expected to be more than 30% of estimated blood volume, or cases where fluid imbalance is expected to be severe during surgery patients scheduled for lung parenchyme/diaphragm/thoracic surgery other researchers considered it inappropriate to participate in research.
Sites / Locations
- Seoul National University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Neostigmine
Sugammadex
The use of neostigmine 0.02mg/kg for reversal of neuromuscular blocking agent.
The use of sugammadex 2mg/kg for reversal of neuromuscular blocking agent.